"-TDLo oral 17mg/kg (human) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX). PMID: 13535337. -LD50 intraperitoneal 116mg/kg (mouse) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD. PMID: 13062090. -LD50 intravenous 72mg/kg (mouse) BEHAVIORAL: ATAXIA. PMID: 14109651."@en . "Captodiame, also known as captodiamine, is an antihistamine which is used as a sedative and anxiolytic. It is a derivative of diphenhydramine. Captodiame has been suggested for use in preventing benzodiazepine withdrawal syndrome."@en . . "approved"@en . . . "Captodiamine synthesis: Hubner Oluf Herman, Petersen Povl Viggo. U.S. Patent 2,830,088 (1958)."@en . "Captodiame"@en . . . . . "Renal. "@en . " "@en . "2-[(4-butylsulfanylphenyl)-phenyl-methyl]sulfanyl-N,N-dimethylethanamine"@en . . . "investigational"@en . . "Captodiame"@en . . . "Captodiame is indicated for the treatment of anxiety. "@en . . . . . . . . . . . . . . "486-17-9"@en . . . . . . . . . "# Mercier-Guyon C, Chabannes JP, Saviuc P: The role of captodiamine in the withdrawal from long-term benzodiazepine treatment. Curr Med Res Opin. 2004 Sep;20(9):1347-55. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15383182 # http://chem.sis.nlm.nih.gov/chemidplus/rn/486-17-9 # PENTNEY BH, BROTHERWOOD RW: Captodiame in anxiety states in general practice. Practitioner. 1960 Aug;185:218-21. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14431646"@en . .